417 related articles for article (PubMed ID: 36299588)
1. Overexpression of
Yang P; Liu H; Li Y; Gao Q; Chen X; Chang J; Li Y; Chen S; Dong R; Wu H; Liu C; Liu G
Front Genet; 2022; 13():959832. PubMed ID: 36299588
[No Abstract] [Full Text] [Related]
2. Overexpression of NOP58 as a Prognostic Marker in Hepatocellular Carcinoma: A TCGA Data-Based Analysis.
Wang J; Huang R; Huang Y; Chen Y; Chen F
Adv Ther; 2021 Jun; 38(6):3342-3361. PubMed ID: 34014550
[TBL] [Abstract][Full Text] [Related]
3. CPNE1 is a potential prognostic biomarker, associated with immune infiltrates and promotes progression of hepatocellular carcinoma.
Su J; Huang Y; Wang Y; Li R; Deng W; Zhang H; Xiong H
Cancer Cell Int; 2022 Feb; 22(1):67. PubMed ID: 35139863
[TBL] [Abstract][Full Text] [Related]
4. Over-expression of RRM2 predicts adverse prognosis correlated with immune infiltrates: A potential biomarker for hepatocellular carcinoma.
Qin Z; Xie B; Qian J; Ma X; Zhang L; Wei J; Wang Z; Fan L; Zhu Z; Qian Z; Yin H; Zhu F; Tan Y
Front Oncol; 2023; 13():1144269. PubMed ID: 37056349
[TBL] [Abstract][Full Text] [Related]
5. Centromere protein N may be a novel malignant prognostic biomarker for hepatocellular carcinoma.
Wang Q; Yu X; Zheng Z; Chen F; Yang N; Zhou Y
PeerJ; 2021; 9():e11342. PubMed ID: 33987018
[TBL] [Abstract][Full Text] [Related]
6. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma.
Mu W; Xie Y; Li J; Yan R; Zhang J; Liu Y; Fan Y
World J Surg Oncol; 2022 Jan; 20(1):22. PubMed ID: 35065633
[TBL] [Abstract][Full Text] [Related]
7. ERCC3-Related Genes May Aid in the Prognostic and Immunotherapeutic Analysis of Hepatocellular Carcinoma.
Yang C; Chen Y; Tao T; Xu P; Li M; Deng B; Lu S; Yang M; Wang W; Wang J; Liu S
Comb Chem High Throughput Screen; 2024 Jun; ():. PubMed ID: 38859773
[TBL] [Abstract][Full Text] [Related]
8. Expression of tumor-associated macrophages and PD-L1 in patients with hepatocellular carcinoma and construction of a prognostic model.
Kong P; Yang H; Tong Q; Dong X; Yi MA; Yan D
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10685-10700. PubMed ID: 37306737
[TBL] [Abstract][Full Text] [Related]
9. Increased CDCA2 Level Was Related to Poor Prognosis in Hepatocellular Carcinoma and Associated With Up-Regulation of Immune Checkpoints.
Tang M; Liao M; Ai X; He G
Front Med (Lausanne); 2021; 8():773724. PubMed ID: 35372372
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of Stress-Induced Protein Kinase CK1 Delta is associated with a Poor Prognosis for patients with Hepatocellular Carcinoma.
Zhang H; Qiu C; Zeng H; Zhu W; Lyu W; Lao X
Genet Test Mol Biomarkers; 2021 Jul; 25(7):504-514. PubMed ID: 34280005
[No Abstract] [Full Text] [Related]
11. High expression of TBRG4 in relation to unfavorable outcome and cell ferroptosis in hepatocellular carcinoma.
Tao S; Cui D; Cheng H; Liu X; Jiang Z; Chen H; Gao Y
BMC Cancer; 2024 Feb; 24(1):194. PubMed ID: 38347489
[TBL] [Abstract][Full Text] [Related]
12. Characterization of prognostic value and immunological roles of RAB22A in hepatocellular carcinoma.
Wen F; Meng F; Li X; Li Q; Liu J; Zhang R; Zhao Y; Zhang Y; Wang X; Ju S; Cui Y; Lu Z
Front Immunol; 2023; 14():1086342. PubMed ID: 36936971
[TBL] [Abstract][Full Text] [Related]
13. RBM39 is a potential prognostic biomarker with functional significance in hepatocellular carcinoma.
Cui F; Wang W; Zhuang C; He D; Wang P
Transl Cancer Res; 2024 Apr; 13(4):1606-1622. PubMed ID: 38737697
[TBL] [Abstract][Full Text] [Related]
14. Increased expression of Cyclin F in liver cancer predicts poor prognosis: A study based on TCGA database.
Zelong Y; Han Y; Ting G; Yifei W; Kun H; Haoran H; Yong C
Medicine (Baltimore); 2021 Aug; 100(31):e26623. PubMed ID: 34397798
[TBL] [Abstract][Full Text] [Related]
15. Elevated Small Nuclear Ribonucleoprotein Polypeptide an Expression Correlated With Poor Prognosis and Immune Infiltrates in Patients With Hepatocellular Carcinoma.
Zhang Y; Wang X; Wang H; Jiang Y; Xu Z; Luo L
Front Oncol; 2022; 12():893107. PubMed ID: 35860579
[TBL] [Abstract][Full Text] [Related]
16. AP4M1 as a prognostic biomarker associated with cell proliferation, migration and immune regulation in hepatocellular carcinoma.
Peng Y; Li X; Kang K; Zhou Y
Cancer Cell Int; 2023 Oct; 23(1):235. PubMed ID: 37821948
[TBL] [Abstract][Full Text] [Related]
17. Abnormal Expression of Centromere Protein U Is Associated with Hepatocellular Cancer Progression.
Yu Y; Chen X; Zhang W; Liu J
Biomed Res Int; 2021; 2021():4051192. PubMed ID: 34957303
[TBL] [Abstract][Full Text] [Related]
18. [TMEM64 is highly expressed in hepatocellular carcinoma and promotes tumor cell proliferation and invasion].
Cao D; Cai J; Li Y; Dong R; Wang Z; Zuo X
Nan Fang Yi Ke Da Xue Xue Bao; 2023 Aug; 43(8):1345-1355. PubMed ID: 37712271
[TBL] [Abstract][Full Text] [Related]
19. The Biological Function of POLA2 in Hepatocellular Carcinoma.
Yang Z; Shen X; Wang Z; Li R; Hou W; Liu Z; Gao Y; Zhu C; Qin X
Comb Chem High Throughput Screen; 2023 Oct; ():. PubMed ID: 37861044
[TBL] [Abstract][Full Text] [Related]
20. Identification of CFHR4 as a Potential Prognosis Biomarker Associated With lmmune Infiltrates in Hepatocellular Carcinoma.
Yu H; Wang C; Ke S; Bai M; Xu Y; Lu S; Feng Z; Qian B; Xu Y; Zhou M; Li Z; Yin B; Li X; Hua Y; Zhou Y; Pan S; Fu Y; Ma Y
Front Immunol; 2022; 13():892750. PubMed ID: 35812416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
